Clear Search sequence regions
Bookmark Forward

QuickView for Pyridostigmine (compound)


PubChem
Name: Pyridostigmine Bromide
PubChem Compound ID: 4991
Description: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
Molecular formula: C9H13N2O2+
Molecular weight: 181.212 g/mol
Synonyms:
KBioSS_002083; Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl- (9CI); DivK1c_000207; NCGC00015862-01; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); NCI60_028530; 155-97-5; Lopac-P-9797; KBio2_004651; Spectrum_001603.
show more »
DrugBank
Identification
Name: Pyridostigmine Bromide
Name (isomeric): DB00545
Drug Type: small molecule
Description: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
Synonyms:
Pyridostigminum; Pyridostigmine Bromine; Pyridine N-Oxide; Pyridostigmine Bromide
Brand: Mestinon, Regonol, Mestinon-SR
Category: Parasympathomimetics, Cholinesterase Inhibitors, Antimyasthenics
CAS number: 155-97-5
Pharmacology
Indication: For the treatment of myasthenia gravis.
Pharmacology:
Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier. Pyridostigmine has a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle...
show more »
Mechanism of Action: Pyridostigmine inhibits acetylcholinesterase in the synaptic cleft by competing with acetylcholine for attachment to acetylcholinesterase, thus slowing down the hydrolysis of acetylcholine, and thereby increases efficiency of cholinergic transmission in the neuromuscular junction and prolonges the effects of acetylcholine.
Absorption: Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.
Biotransformation: Hydrolysis by cholinesterases and by liver.
Half Life: 3 hours following oral administration.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Take with food to decrease adverse effects.
Drug interaction:
BetamethasoneThe corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
Cortisone acetateThe corticosteroid, cortisone acetate, may decrease the effect of the anticholinesterase, pyridostigmine.
PrednisoloneThe corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.
FludrocortisoneThe corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.
DexamethasoneThe corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
show more »

Targets


Enzymes